Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trypanosoma cruzi mucins are a family of heavily glycosylated surface proteins that form a dense layer covering the parasite. They are involved in host cell attachment and invasion, as well as protecting the parasite from the host's immune system. TcMUC I is predominant in amastigotes, while TcMUC II dominates trypomastigote membrane lipid rafts. These proteins have O-glycosylation sites flanked by signal peptides/GPI-anchor signals, making them potential targets for therapeutic intervention aimed at blocking parasite-host interactions.
Unknown; potential target for blocking host cell interaction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Trypanosoma cruzi Mucin (TcMUC).